Takeda’s claim that Apotex infringed a patent relating to Takeda’s heartburn drug was denied by the Federal Court of Canada on the basis that Takeda products contained two doses of dexlansoprazole, whereas Apotex products only contained one dose.
Communications Law
Takeda’s claim that Apotex infringed a patent relating to Takeda’s heartburn drug was denied by the Federal Court of Canada on the basis that Takeda products contained two doses of dexlansoprazole, whereas Apotex products only contained one dose.